Cited by 274Lipoproteins and Cardiovascular HealthStatistical Methods in Clinical TrialsPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

Open access

Wood, Frances A., Howard, James P., Finegold, Judith A., Nowbar, Alexandra N., Thompson, David M., Arnold, Ahran D., Rajkumar, Christopher A., Connolly, Susan, Cegla, Jaimini, Stride, Chris, Sever, Peter, Norton, Christine, Thom, Simon A.M., Shun-Shin, Matthew J., Francis, Darrel P.·2020·New England Journal of Medicine

DOI 10.1056/nejmc2031173

Open this paper in CoChat — free account Open PDF

Abstract

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side EffectsTo the Editor: Statins are often discontinued because of side effects, 1,2 even though some blinded trials have not shown an excess of symptoms with statins as compared with placebo.3,4 Patients who had previously discontinued statins because of side effects that occurred within 2 weeks after the initiation of treatment were enrolled in a double-blind, three-group, n-of-1 trial to test whether symptoms would be induced by a statin or placebo.Details of the trial methods are provided in Section S2 in the Supplementary Appendix (available with the full text of this letter at NEJM.org); the trial protocol and statistical analysis plan are also available at NEJM.org.The patients received four bottles containing atorvastatin at a dose of 20 mg, four bottles containing placebo, and four empty bottles; each bottle was to be used for a 1-month period according to a random sequence.The patients used a smartphone application to report symptom intensity daily.Symptom scores ranged from 0 (no symptoms) to 100 (worst imaginable symptoms).If the patients determined that their symptoms were unacceptably severe, they could discontinue the tablets for that month.The primary end point was symptom intensity as assessed with the use of the nocebo ratio (i.e., the ratio of symptom intensity induced by taking placebo to the symptom intensity induced by taking a statin).This ratio was calculated as the symptom intensity with placebo minus the symptom intensity with neither statin nor placebo, divided by the symptom intensity with a statin minus the symptom intensity with neither statin nor placebo.From June 2016 through March 2019, a total of 60 patients underwent randomization.The screening data, the baseline characteristics of the

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmc2031173

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31075-9 · Cited by 343
Self-citation
What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice
Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314525531 · Cited by 214
Self-citation
Statin Intolerance: the Clinician’s Perspective
Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 59

Show all 4 references

Sorted by citations

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Covington, A. M., DePalma, S. M., Minissian, M. B., Orringer, C. E., Smith, S. C., Waring, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.006 · Cited by 569
Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication
Nordanstig, J., Behrendt, C., Baumgärtner, I., Belch, J. J. F., Bäck, M., Fitridge, R., Hinchliffe, R. J., Lejay, A., Mills, J. L., Rother, U., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 575
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 529
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022) · JAMA · doi:10.1001/jama.2022.12138 · Cited by 287
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Self-citation
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 237
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.022 · Cited by 198
Self-citation
Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 218
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
Herrett, E., Williamson, E., Brack, K., Beaumont, D., Perkins, A., Thayne, A., Shakur-Still, H., Roberts, I., Prowse, D., Goldacre, B., et al. (2021) · BMJ · doi:10.1136/bmj.n135 · Cited by 191
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
Nelson, A. J., Haynes, K., Shambhu, S., Eapen, Z. J., Cziraky, M. J., Nanna, M. G., Calvert, S. B., Gallagher, K., Pagidipati, N. J., & Granger, C. B. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.048 · Cited by 157
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 139
The importance of small samples in medical research
Indrayan, A., & Mishra, A. (2021) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_230_21 · Cited by 108
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
Ray, K. K., Nicholls, S. J., Li, N., Louie, M. J., Brennan, D., Lincoff, A. M., & Nissen, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00316-9 · Cited by 99
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Krychtiuk, K. A., Ahrens, I., Drexel, H., Halvorsen, S., Hassager, C., Huber, K., Kurpas, D., Niessner, A., Schiele, F., Semb, A. G., et al. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac123 · Cited by 100
Lipid Lowering Therapy: An Era Beyond Statins
Abdul‐Rahman, T., Bukhari, S. M. A., Cantu‐Herrera, E., Awuah, W. A., Lawrence, J. A., de Andrade, H., Patel, N., Shah, R. M., Shaikh, R., Capriles, C. A. A., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101342 · Cited by 94
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 87
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
Underberg, J. A., Toth, P. P., & Rodríguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 81
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations
Hao, Q., Aertgeerts, B., Guyatt, G. H., Bekkering, G. E., Vandvik, P. O., Khan, S. U., Rodondi, N., Jackson, R., Reny, J., Al‐Ansary, L. A., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069066 · Cited by 80
Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone
Yogev, Y., Shorer, Z., Koifman, A., Wormser, O., Drabkin, M., Halperin, D. S., Dolgin, V., Proskorovski‐Ohayon, R., Hadar, N., Davidov, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217831120 · Cited by 61
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M. V., Tassell, B. W. V., Jiménez, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.021 · Cited by 59
Antibiotics versus placebo in adults with CT-confirmed uncomplicated acute appendicitis (APPAC III): randomized double-blind superiority trial
Salminen, P. T. P., Sippola, S., Haijanen, J., Nordström, P., Rantanen, T. K., Rautio, T., Sallinen, V. J., Löyttyniemi, E., Hurme, S. A. M., Tammilehto, V., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac086 · Cited by 59
Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults
Kohli-Lynch, C. N., Bellows, B. K., Zhang, Y., Spring, B. J., Kazi, D. S., Pletcher, M. J., Vittinghoff, E., Allen, N. B., & Moran, A. E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.065 · Cited by 54
What Do Placebo and Nocebo Effects Have to Do With Health Equity? The Hidden Toll of Nocebo Effects on Racial and Ethnic Minority Patients in Clinical Care
Yetman, H. E., Cox, N., Adler, S. R., Hall, K. T., & Stone, V. E. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.788230 · Cited by 52
Establishment of an International Collaborative Network for N-of-1 Trials and Single-Case Designs
Nikles, J., Onghena, P., Vlaeyen, J. W. S., Wicksell, R. K., Simons, L. E., McGree, J. M., & McDonald, S. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100826 · Cited by 52
A Useful and Sustainable Role for N‐of‐1 Trials in the Healthcare Ecosystem
Selker, H. P., Cohen, T., D’Agostino, R. B., Dere, W. H., Ghaemi, S. N., Honig, P. K., Kaitin, K. I., Kaplan, H. C., Kravitz, R. L., Larholt, K. M., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2425 · Cited by 48
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
Penson, P. E., & Banach, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab358 · Cited by 48
LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis
Schreuder, M. M., Hamkour, S., Siegers, K. E., Holven, K. B., Johansen, A. K., van de Ree, M. A., Imholz, B. P. M., Boersma, E. H., Louters, L., Bogsrud, M. P., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.022 · Cited by 48
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?
Ferhatbegović, L., Mršić, D., Kušljugić, S., & Pojskić, B. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01037-3 · Cited by 42
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Davis, J. W., & Weller, S. C. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043714 · Cited by 46
Gaps and Disparities in Primary Prevention Statin Prescription During Outpatient Care
Metser, G., Bradley, C., Moise, N., Liyanage-Don, N. A., Kronish, I. M., & Ye, S. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.08.070 · Cited by 41
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00932-5 · Cited by 35
Statins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study
Bergqvist, R., Ahlqvist, V. H., Lundberg, M., Hergens, M., Sundström, J., Bell, M., & Magnusson, C. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003820 · Cited by 33
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Placebo and nocebo effects: from observation to harnessing and clinical application
Tu, Y., Zhang, L., & Kong, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02293-2 · Cited by 34
Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017–2020
Chobufo, M. D., Regner, S. R., Zeb, I., Lacoste, J. L., Virani, S. S., & Balla, S. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac103 · Cited by 31
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 32
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 30
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 28
Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin
Lu, B. D., Sun, L., Seraydarian, M., Hoffmann, T. J., Medina, M. W., RISCH, N. J., Iribarren, C., Krauss, R. M., & Oni‐Orisan, A. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2337 · Cited by 26
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 27
Evaluating Readability, Understandability, and Actionability of Online Printable Patient Education Materials for Cholesterol Management: A Systematic Review
Bhatt, C., Lin, E., Legere, L., Jackevicius, C. A., Ko, D. T., Lee, D. S., Schade, K., Johnston, S., Anderson, T. J., & Udell, J. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030140 · Cited by 25
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 26
Management of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 27
SAMSON and the Nocebo Effect: Management of Statin Intolerance
Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25
Using deep learning-based natural language processing to identify reasons for statin nonuse in patients with atherosclerotic cardiovascular disease
Sarraju, A., Coquet, J., Zammit, A., Chan, A., Ngo, S., Hernandez‐Boussard, T., & Rodríguez, F. (2022) · Communications Medicine · doi:10.1038/s43856-022-00157-w · Cited by 25
N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case study
Goyal, P., Safford, M. M., Hilmer, S. N., Steinman, M. A., Matlock, D. D., Maurer, M. S., Lachs, M. S., & Kronish, I. M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15442 · Cited by 22
Guidelines for the management of hyperlipidemia: How can clinicians effectively implement them?
Dembowski, E., Freedman, I. G., Grundy, S. M., & Stone, N. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.009 · Cited by 25
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Statin-related Muscle Toxicity: An Evidence-based Review
Jeeyavudeen, M. S., Pappachan, J. M., & Arunagirinathan, G. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.89 · Cited by 21
Primary prevention statin therapy in older adults
Nanna, M. G., Abdullah, A., Mortensen, M. B., & Návar, A. M. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001003 · Cited by 28
Learnings from Implementation Strategies to Improve Lipid Management
Lan, N. S. R., Chen, R. T., Dwivedi, G., Watts, G. F., Nicholls, S. J., & Nelson, A. J. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02174-8 · Cited by 20
Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis
Keyes, E., Grinnell, M., Jacoby, D. S., Vazquez, T., Diaz, D., Werth, V. P., & Williams, K. J. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.08.015 · Cited by 21
Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
Katzmann, J. L., Kieble, M., Enners, S., Böhm, M., Mahfoud, F., Laufs, U., & Schulz, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.912785 · Cited by 20
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 22
Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction
Vera, O. D., Wulff, H., & Braun, A. P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1151244 · Cited by 20
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 19
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women
van Oortmerssen, J. A. E., Mulder, J. W. C. M., van der Bijl, M. F., Mijnster, R. J. M., Kavousi, M., & van Lennep, J. E. R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01275-1 · Cited by 19
Identifying Reasons for Statin Nonuse in Patients With Diabetes Using Deep Learning of Electronic Health Records
Sarraju, A., Zammit, A., Ngo, S., Witting, C. S., Hernandez‐Boussard, T., & Rodríguez, F. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028120 · Cited by 18
Drucebo effect – the challenge we should all definitely face!
Banach, M., & Penson, P. E. (2021) · Archives of Medical Science · doi:10.5114/aoms/132304 · Cited by 18
How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic?
Amanzio, M., Cipriani, G. E., & Bartoli, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900728 · Cited by 16
Nocebo affects after COVID-19 vaccination
Sever, P. S. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100273 · Cited by 18
Self-citation
N‐of‐1 trials in epilepsy: A systematic review and lessons paving the way forward
Defelippe, V. M., Brilstra, E. H., Otte, W. M., Cross, J. H., O'Callaghan, F. J., GIORGIS, V. D., Poduri, A., Lerche, H., Sisodiya, S. M., Braun, K. P. J., et al. (2024) · Epilepsia · doi:10.1111/epi.18068 · Cited by 16
Statin intolerance: new data and further options for treatment
Diaconu, C. C., Iorga, R., Furtunescu, F., Katsiki, N., Stoian, A. P., & Rizzo, M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000874 · Cited by 17
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17
Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial
Zafeiropoulos, S., Farmakis, I. T., Κάρτας, Α., Arvanitaki, A., Pagiantza, A., Boulmpou, A., Tampaki, A., Kosmidis, D., Nevras, V., Markidis, E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.013 · Cited by 16
State of the Art: Therapie mit Statinen
Laufs, U., Weingärtner, O., Kassner, U., & Schatz, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2471 · Cited by 16
Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
Patel, P. N., & Giugliano, R. P. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.39 · Cited by 19
Statin intolerance: how common is it and how do we work with patients to overcome it?
Cannon, C. P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac156 · Cited by 15
Eradicating Atherosclerosis: Should We Start Statins at Younger Ages and at Lower LDL-Cs
O'Toole, T. E., Kelsey, M. D., Shah, N. P., McGarrah, R. W., & Pagidipati, N. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01760-y · Cited by 15
Incidence of Statin-Associated Adverse Events in Kidney Transplant Recipients
Bae, S., Ahn, J. B., Joseph, C., Whisler, R., Schnitzler, M. A., Lentine, K. L., KADOSH, B. S., Segev, D. L., & McAdams‐DeMarco, M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000124 · Cited by 13
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus
Zhao, M., Feng, R., Werth, V. P., & Williams, K. J. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000908 · Cited by 14
Statin intolerance and new lipid-lowering treatments
Mesi, O., Lin, C., Ahmed, H. M., & Cho, L. S. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20165 · Cited by 15
Statin-Related New-Onset Diabetes Appears Driven by Increased Insulin Resistance: Are There Clinical Implications?
Brinton, E. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316893 · Cited by 14
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?
Jamil, Y., Cohen, R., Alameddine, D., Deo, S. V., Kumar, M., & Orkaby, A. R. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01224-4 · Cited by 13
Benefits and limitations of statin use in primary cardiovascular prevention: recent advances
Strandberg, T. E. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16258 · Cited by 13
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Malick, W. A., Choi, D., Langsted, A., Bittner, V., Nordestgaard, B. G., Stroes, E. S. G., & Rosenson, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf123 · Cited by 14
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial
Cha, J., Hong, S. J., Kim, J. H., Lim, S., Joo, H. J., Park, J. H., Yu, C. W., Lee, P. H., Lee, S., Lee, C. W., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.03.002 · Cited by 12
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
Kearney, A., Linden, K., Savage, P., & Menown, I. B. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01711-z · Cited by 13
Statin Intolerance and Noncompliance: An Empiric Approach
Grundy, S. M., & Vega, G. L. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.09.014 · Cited by 12
Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
Mihaylova, B., Wu, R., Zhou, J., Williams, C., Schlackow, I., Emberson, J., Reith, C. A., KEECH, A. C., Robson, J. P., Parnell, R., et al. (2024) · Heart · doi:10.1136/heartjnl-2024-324052 · Cited by 11
Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context
Rifai, M. A., Blumenthal, R. S., Stone, N. J., Schofield, R. S., Orringer, C. E., Michos, E. D., Heidenreich, P. A., Braun, L. T., Birtcher, K. K., Smith, S. C., et al. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.08.001 · Cited by 11
National Asthma Education and Prevention Program 2020 Guidelines: What’s Important for Primary Care
Murphy, M. (2021) · The Journal of Family Practice · doi:10.12788/jfp.0219 · Cited by 14
Inclisiran for the Treatment of Hyperlipidemia and for Atherosclerotic Cardiovascular Disease Risk Reduction: A Narrative Review
Cowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11
Personalizing cholesterol treatment recommendations for primary cardiovascular disease prevention
Sarraju, A., Ward, A., Li, J., Valencia, A., Palaniappan, L. P., Scheinker, D., & Rodríguez, F. (2022) · Scientific Reports · doi:10.1038/s41598-021-03796-6 · Cited by 11
Harnessing placebo effects and mitigating nocebo effects: implications for clinical practice in psychiatry and medicine
Burke, M. J., Sandra, D. A., Peciña, M., Olson, J. A., Mollica, A., Butler, M., Moss, J. H., Nicholson, T. R., Wager, T. D., & Kaptchuk, T. J. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00340-2 · Cited by 12
Drug-induced Myopathies
Steinmeyer, J., & Flechtenmacher, J. (2021) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/a-1488-6912 · Cited by 10
Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis
Salem, A. M. H., Harris, D. E., Bray, J. J. H., Obaid, D. R., Stephens, J. W., & Halcox, J. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.02.004 · Cited by 10
Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom
Reynolds, T., Pottle, A., & Quoraishi, S. H. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s269879 · Cited by 10
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin‐Associated Muscle Symptoms
Lauritzen, T., Munkhaugen, J., Peersen, K., Kristiansen, O., Sverre, E., Nebauer, S., Villseth, M., Andersen, A., Svarstad, A. C., Jensen, E. P., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2844 · Cited by 10
Safety and efficacy of moderate‐intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease
Cha, J., Kim, J. H., Hong, S. J., Lim, S., Joo, H. J., Park, J. H., Yu, C. W., Lee, P. H., Lee, S., Lee, C. W., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20029 · Cited by 10
Nocebo effects in the treatment of endometriosis
Thiel, P., Burke, M. J., Bridge-Cook, P., & Leonardi, M. (2021) · Reproduction and Fertility · doi:10.1530/raf-21-0040 · Cited by 9
Factors associated with early nonpersistence among patients experiencing side effects from a new medication
Alefan, Q., Yao, S., Taylor, J. G., Lix, L. M., Eurich, D. T., Choudhry, N. K., & Blackburn, D. F. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.12.001 · Cited by 9
Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care
Tudor, K., Brooks, J., Howick, J., Fox, R., & Aveyard, P. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007793 · Cited by 9
Time for N-of-1 trials in clinical decision-making
Husain, M. (2021) · Brain · doi:10.1093/brain/awab107 · Cited by 9
Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty
Jhaveri, A., Sibley, R. A., Spatz, E. S., & Dodson, J. A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01499-y · Cited by 10

Authors: Wood, F. A., Howard, J. P., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., Sever, P., Norton, C., Thom, S. A. M., Shun-Shin, M. J., & Francis, D. P.
Affiliations: Imperial College London (GB)
Imperial College Healthcare NHS Trust (GB)
University of Sheffield (GB)
King's College London (GB)
Imperial College London, London, United Kingdom
ORCID: Howard, James P.
Nowbar, Alexandra N.
Arnold, Ahran D.
Rajkumar, Christopher A.
Connolly, Susan
Cegla, Jaimini
Stride, Chris
Sever, Peter
Norton, Christine
Thom, Simon A.M.
Shun-Shin, Matthew J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-11-26
Volume: 383
Issue: 22
Pages: 2182-2184
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmc2031173
OpenAlex: W3104495732
Cited by: 274
References: 4
Citations by year: 2026: 29 · 2025: 25 · 2024: 29 · 2023: 37 · 2022: 59 · 2021: 92 · 2020: 3
FWCI: 43.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
Funders: British Heart Foundation (PG/15/7/31235)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: statins, atorvastatin, adverse drug reactions, nocebo effect, placebo response, symptom intensity, N-of-1 trials, statin discontinuation
MeSH terms: Atorvastatin, Adult, Double-Blind Method, Humans, Placebos, Confidence Intervals, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks